Research on hidradenitis suppurativa (HS) has redefined the condition as a systemic inflammatory disease, moving away from the previous concept of follicular occlusion. Treatment strategies are evolving with the use of targeted anti-inflammatory therapies such as bimekizumab. Studies have shown that HS activity is not limited to lesional skin, with inflammation also found in non-lesional skin. Early diagnosis and treatment are crucial for better outcomes in HS, as advanced disease can develop quickly. Researchers are exploring new strategies to target the disease, including potential interventions targeting bacteria and inflammatory factors. Identifying inflammatory phenotypes may help personalize treatment choices for HS.
Source link
Recharacterization of HS Pathology Underway
